Floatz logo

Oliceridine

Burns

University of TennesseeSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Burns cohort.

Same molecule, other indications

Oliceridine is also rated in:

Adverse Drug EventDormant
BB
Indicative ·
69 / 100
View asset →
respiratory failureDormant
BB
Indicative ·
69 / 100
View asset →
Acute PainDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →